Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Clinical Trial ID NCT02032823

Rank	Title	Journal	Year	PubWeight™‹?›
1	Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.	J Clin Oncol	2015	1.41
2	Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.	Nat Rev Clin Oncol	2016	1.18
3	PARP inhibitors in the management of breast cancer: current data and future prospects.	BMC Med	2015	1.16
4	Biology of breast cancer in young women.	Breast Cancer Res	2014	0.98
5	Targeted Therapies in Triple-Negative Breast Cancer.	Breast Care (Basel)	2015	0.96
6	Triple-negative breast cancer: treatment challenges and solutions.	Breast Cancer (Dove Med Press)	2016	0.95
7	Biology and Management of Patients With Triple-Negative Breast Cancer.	Oncologist	2016	0.84
8	Trial watch - inhibiting PARP enzymes for anticancer therapy.	Mol Cell Oncol	2015	0.79
9	Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network.	Geburtshilfe Frauenheilkd	2015	0.78
10	Recent developments and translational aspects in targeted therapy for metastatic breast cancer.	ESMO Open	2016	0.76
11	Neoadjuvant Treatment of Breast Cancer - Advances and Limitations.	Breast Care (Basel)	2016	0.75